Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Methylmalonic Acidemia (MMA)

Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Methylmalonic acidemia/isolated methylmalonic acidemia/methylmalonic aciduria/MMA refers to a group of inherited conditions in which the body can’t breakdown certain parts of proteins and fats. This leads to a build-up of toxic substances and bouts of serious illness called decompensation events or metabolic crises. Isolated methylmalonic acidemia is caused by changes in one of five genes: MMUT, MMAA, MMAB, MMADHC, or MCEE. Methylmalonic acidemia with homocystinuria is caused by mutations in the MMADHC, LMBRD1 and ABCD4 genes. Other forms of methylmalonic acidemia are caused by changes in different genes.

Epidemiology- According to literature review and Thelansis estimation, about 1/80,000-1/100,000 babies are born with methylmalonic acidemia worldwide. In the United States, one study estimated that about 1/90,000 babies are born with methylmalonic acidemia.

Competitive landscape of Methylmalonic Acidemia (MMA) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Methylmalonic Acidemia (MMA) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Methylmalonic Acidemia (MMA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Methylmalonic Acidemia (MMA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Companies        Asset        Status

1        Recordati        Carglumic acid        Marketed in EU

2        ModernaTX, Inc.        mRNA 3704        Phase I/II

3        HemoShear Therapeutics        HST-103        In pre-clinical

4        HemoShear Therapeutics        HST-104        In pre-clinical

5        HemoShear Therapeutics        methylmalonic acidemia        In pre-clinical

6        LogicBio        LB-001        In pre-clinical

7        Selecta Biosciences        SEL-302        In pre-clinical